Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

"These are now the most promising drugs in pancreatic and other cancers such as lung cancer and colon cancer," said Sohal. "These are the so-called RAS inhibitors." Research indicates that RAS ...

Shaw and Andrew Aguirre, an oncologist and pancreatic cancer researcher, are co-leading the newly launched Center for RAS Therapeutics, coordinating the prosecution of drugs aimed at KRAS ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.